MMWR Morb Mortal Wkly Rep. 2023 Feb 17;72(7):190-198. doi: 10.15585/mmwr.mm7207a5.
COVID-19 vaccine booster doses are safe and maintain protection after receipt of a primary vaccination series and reduce the risk for serious COVID-19-related outcomes, including emergency department visits, hospitalization, and death (1,2). CDC recommended an updated (bivalent) booster for adolescents aged 12-17 years and adults aged ≥18 years on September 1, 2022 (3). The bivalent booster is formulated to protect against the Omicron BA.4 and BA.5 subvariants of SARS-CoV-2 as well as the original (ancestral) strain (3). Based on data collected during October 30-December 31, 2022, from the National Immunization Survey-Child COVID Module (NIS-CCM) (4), among all adolescents aged 12-17 years who completed a primary series, 18.5% had received a bivalent booster dose, 52.0% had not yet received a bivalent booster but had parents open to booster vaccination for their child, 15.1% had not received a bivalent booster and had parents who were unsure about getting a booster vaccination for their child, and 14.4% had parents who were reluctant to seek booster vaccination for their child. Based on data collected during October 30-December 31, 2022, from the National Immunization Survey-Adult COVID Module (NIS-ACM) (4), 27.1% of adults who had completed a COVID-19 primary series had received a bivalent booster, 39.4% had not yet received a bivalent booster but were open to receiving booster vaccination, 12.4% had not yet received a bivalent booster and were unsure about getting a booster vaccination, and 21.1% were reluctant to receive a booster. Adolescents and adults in rural areas had a much lower primary series completion rate and up-to-date vaccination coverage. Bivalent booster coverage was lower among non-Hispanic Black or African American (Black) and Hispanic or Latino (Hispanic) adolescents and adults compared with non-Hispanic White (White) adolescents and adults. Among adults who were open to receiving booster vaccination, 58.9% reported not having received a provider recommendation for booster vaccination, 16.9% had safety concerns, and 4.4% reported difficulty getting a booster vaccine. Among adolescents with parents who were open to getting a booster vaccination for their child, 32.4% had not received a provider recommendation for any COVID-19 vaccination, and 11.8% had parents who reported safety concerns. Although bivalent booster vaccination coverage among adults differed by factors such as income, health insurance status, and social vulnerability index (SVI), these factors were not associated with differences in reluctance to seek booster vaccination. Health care provider recommendations for COVID-19 vaccination; dissemination of information by trusted messengers about the continued risk for COVID-19-related illness and the benefits and safety of bivalent booster vaccination; and reducing barriers to vaccination could improve COVID-19 bivalent booster coverage among adolescents and adults.
COVID-19 疫苗加强针在接种完基础免疫系列后是安全的,并能保持对 COVID-19 的保护作用,降低因 COVID-19 而出现严重后果(包括急诊、住院和死亡)的风险(1,2)。CDC 于 2022 年 9 月 1 日建议为 12-17 岁青少年和 18 岁及以上成年人接种更新的(二价)加强针(3)。这种二价加强针的配方可以预防 SARS-CoV-2 的奥密克戎 BA.4 和 BA.5 亚变种以及原始(祖先)株(3)。根据 2022 年 10 月 30 日至 12 月 31 日从国家免疫调查-儿童 COVID 模块(NIS-CCM)(4)收集的数据,在所有完成基础免疫系列的 12-17 岁青少年中,有 18.5%的人接种了二价加强针,52.0%的人尚未接种二价加强针,但家长愿意为孩子接种加强针,15.1%的人尚未接种二价加强针,家长对为孩子接种加强针持不确定态度,14.4%的家长不愿意为孩子接种加强针。根据 2022 年 10 月 30 日至 12 月 31 日从国家免疫调查-成人 COVID 模块(NIS-ACM)(4)收集的数据,27.1%完成了 COVID-19 基础免疫系列的成年人接种了二价加强针,39.4%的人尚未接种二价加强针,但愿意接种加强针,12.4%尚未接种二价加强针,对接种加强针持不确定态度,21.1%的人不愿意接种加强针。农村地区的青少年和成年人基础免疫系列完成率和最新疫苗接种率都低得多。与非西班牙裔白种人(白人)青少年和成年人相比,非裔黑种人或非裔美国人(黑人)和西班牙裔或拉丁裔(西班牙裔)青少年和成年人接种二价加强针的比例较低。在愿意接种加强针的成年人中,58.9%的人报告没有收到提供者关于加强针接种的建议,16.9%的人有安全顾虑,4.4%的人报告难以接种加强针。在愿意为孩子接种加强针的青少年中,有 32.4%的人没有收到任何 COVID-19 疫苗接种的提供者建议,11.8%的家长报告了安全顾虑。尽管成年人接种二价加强针的覆盖率因收入、健康保险状况和社会脆弱性指数(SVI)等因素而异,但这些因素与不愿意寻求加强针接种无关。COVID-19 疫苗接种的提供者建议;可信的信息传播者传播有关 COVID-19 相关疾病持续风险以及二价加强针接种的益处和安全性的信息;以及减少接种障碍,可以提高青少年和成年人的 COVID-19 二价加强针接种率。